Eight to 12 weeks later, we observed marked tumor formation from CD49flow implant populations, which, upon flow cytometry analysis, showed increased expression in Epcam-low–CD49f-low tumor populations but also marked increases in CD49f-high expression and Epcam-high populations. The gene discussed is ITGA6; the disease is neoplasm.